Boston Scientific has announced it has completed the acquisition of Nalu Medical, Inc., a medical technology company specialising in a miniaturised, battery-free Peripheral Nerve Stimulation (PNS) system designed to treat chronic pain.
The acquisition was initially announced back in October 2025, with the transaction consisting of an upfront cash payment of approximately 533 million USD according to the press release.
The Nalu system uses mild electrical impulses to interrupt pain signals before they reach the brain and is powered wirelessly by an external disc controlled via a smartphone app. The completion of this acquisition reinforces the company’s leadership in interventional chronic pain, expanding its ability to equip physicians with a comprehensive suite of evidence-based solutions that address multiple pain pathways and help more patients achieve meaningful relief.
Chronic pain remains one of the most prevalent and challenging conditions to treat, affecting an estimated 50 million adults in the U.S. By acquiring Nalu Medical, Boston Scientific formally enters the rapidly advancing Peripheral Nerve Stimulation (PNS) market.
The acquisition of Nalu Medical expands Boston Scientific’s neuromodulation portfolio by adding a solution for localised pain in areas such as the shoulder, lower back, and knee. This strategic expansion complements Boston Scientific’s existing portfolio and provides a more comprehensive, non-opioid solution for physicians and their patients.
